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Glossary 
Care pathway A methodology for the mutual decision making and organization of 
care for a well-defined group of patients during a well-defined period. 
Clinical governance A systematic approach to maintaining and improving the quality of 
patient care within a health system. 
HIV indicator disease/condition A disease or condition suggestive of underlying HIV infection; not 
necessarily only found in the presence of HIV. 
Incidence The rate at which new cases of a condition occur in a susceptible 
population during a specified period; usually expressed as a number 
per 100 000 in a year. 
Indicators Defined measures which are formed from data collected as part of the 
monitoring and evaluation. 
Informed consent Consent by a person to undergo a medical or surgical investigation or 
treatment after the person understands the risks involved in the 
treatment and/or the consequences of the possible results of the 
investigation. 
Partner notification/partner 
referral 
A formal and systematic means of identifying the sexual partner(s) of 
an index patient diagnosed with a sexually transmitted infection and 
informing them of the need for diagnosis and treatment of a possible 
infection. 
Post-test counselling Discussion following a test result designed to provide advice on how to 
proceed in light of the result. 
Pre-test discussion Short focussed discussion explaining the benefits of testing and how 
results are given for the purpose of obtaining informed consent to the 
test. 
Pre-test information Sometimes used to mean the same as pre-test discussion, but also 
describing written information explaining the benefits of testing and 
how results are given (informed consent is then obtained verbally). 
Pre-test counselling Longer intervention including a sexual history and risk assessment 
designed to perform the same functions as pre-test discussion, but also 
to establish the person’s likely response to the possible result. 
Psychosocial care/psychosocial 
support 
A non-therapeutic intervention that helps a person cope with stressors 
at home or at work. 
Prevalence The proportion of a population that are cases with a certain condition 
at a specific point in time. 
Reactive result Result of a screening test initially indicating HIV infection requiring 
confirmation using a diagnostic test. 
Referral pathway A series of steps designed to ensure referral of patients to appropriate 
services. It is developed by establishing relationships between sexual 
health services and relevant healthcare agencies and involves a shared 
understanding and agreed ways of working together to better address 
the sexual health needs of a defined population. 
Routine offer of HIV testing Everyone attending a service, or presenting with a given condition, is 
offered or recommended an HIV test with pre-test discussion but 
without the need for a risk assessment. 
Seroprevalence The proportion of a population at a specific point of time that test 
positive for antibodies to an antigen based on serology. 
Sexual and reproductive health 
services 
Health services that provide family planning, prevention of unsafe 
abortion, management of reproductive tract infections and sexually 
transmitted infections, including HIV, and promotion of sexual health. 
Surveillance The continued watchfulness over the distribution and trends in the 
incidence of disease through the systematic collection, consolidation 
and evaluation of morbidity and mortality reports and other relevant 
data. 
Universal offer/recommendation 
of an HIV test 
Everyone attending a service is offered or recommended an HIV test 
with pre-test discussion but without the need for a risk assessment. 
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1 Introduction 
The number of people infected with HIV continues to rise across Europe, with the epidemic largely concentrated in 
certain sub-populations, including men who have sex with men, migrants (especially those from countries with high 
HIV prevalence) and injecting drug users. Levels of undiagnosed HIV infections are still high. Many people with 
HIV remain undiagnosed until late in the course of infection and so cannot benefit from earlier treatment that 
reduces morbidity and mortality. It is also recognised that persons diagnosed early are less likely to transmit the 
virus because of lower infectivity and changes in risk behaviour. Thus HIV testing, early diagnosis and treatment 
may have both individual and public health benefits.  
In essence a set of laws, guidelines and recommendations applying to HIV testing is in place in all European 
countries. The contents of the regulations range from specific rules targeting HIV testing to wider rules linked to 
quality of care and good medical practice.  
Countries in Europe report high levels of antiretroviral treatment coverage for those known to be HIV positive. The 
issue is the extent to which people living with HIV who need treatment are unaware of their infection. Reported 
rates of HIV testing among intravenous drug users vary considerably across European countries – from less than 1 % 
to 84 %. Among men having sex with men, reported rates vary from less than 1 % to almost 70 %. Data from 
selected countries have shown rates of late diagnosis from 26 % to 53 %. More than half of those patients where a 
CD4 count was performed at the time of diagnosis had a CD4 count of less than 350 cells/mm3 [1]. 
There is a need for action. Low-risk perception is an important barrier to being tested. Patients must be aware of 
their risk and their need to be tested. On the patient side, barriers to actually seek HIV testing are mainly related 
to fear – fear of a serious diagnosis, stigma and discrimination; on the provider side, a main barrier to offering HIV 
testing is reluctance to touch sensitive topics which education and training could overcome. Regarding the testing 
procedure laws, policies and guidelines play a crucial role as they prescribe requirements to support the testing 
procedure, such as confidentiality, counselling, informed consent, partner notification and referral of the HIV-
diagnosed patients to medical and psychosocial care.  
1.1 Scope and purpose of this guidance 
This evidence-based guidance is designed to inform the development, monitoring and evaluation of national HIV 
testing strategies or programmes in the countries of the European Union (EU) and the European Economic Area 
(EEA). 
It is intended to complement the following existing guidance: 
• Scaling up HIV testing and counselling in the WHO European Region as an essential component of efforts to 
achieve universal access to HIV prevention, treatment, care and support. Policy framework [2] 
• European Guideline on HIV Testing [3] 
• Guidance on provider-initiated HIV testing and counselling in health facilities [4] 
• Guidance on testing and counselling for HIV in settings attended by people who inject drugs. Improving 
access to treatment, care and prevention [5] 
The evidence base to support this guidance has been provided by the findings and conclusions of a systematic 
literature search and evidence synthesis presented in the accompanying document HIV testing: Increasing uptake 
and effectiveness in the European Union. Evidence synthesis for Guidance on HIV testing [6]. The points in this 
guidance are referenced, but for a fuller explanation of the rationale for the recommendations, readers are directed 
to the evidence synthesis. 
1.2 Why is it important to test for HIV? 
 
At the end of 2008 there were an estimated 850 000 people with HIV in western and central Europe [7]. The 
survival of many is due to advances in the treatment of HIV infection which have dramatically improved the health 
and life expectancy of those infected. However, the number of people becoming infected each year continues to 
rise, with 25 656 newly diagnosed cases of HIV infection reported by the countries of the EU and EEA in 2008 [7]. 
The European HIV epidemic is largely concentrated in certain sub-populations, including men who have sex with 
men, migrants (especially those from countries with high HIV prevalence) and injecting drug users, although the 
Across Europe the number of people infected with HIV continues to rise, and the problem of late diagnosis has 
been described in many countries. 
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prevalence of HIV among these groups and others may vary considerably within and between countries [7]. (See 
further, Section 2.1). 
There are still high levels of undiagnosed HIV in Europe. It has been estimated that in EU Member States 30 per 
cent of those infected are unaware of their infection [8]. 
 
The problem of late presentation at HIV diagnosis has been described in many countries throughout the world, but 
definitions of late diagnosis vary considerably. Estimates within Europe range from 12 per cent to 61 per cent of 
infections diagnosed late, depending on whether this was defined by CD4 count at presentation, presentation with 
AIDS at diagnosis or progression to AIDS within varying timeframes following diagnosis [9–11]. 
A late diagnosis of HIV infection (i.e. when the CD4 count is less than 350 cells/mm3 and antiretroviral therapy 
should therefore have started in line with current clinical guidelines [12], or a patient presents with AIDS [13]) 
results in a very much higher probability of morbidity and mortality [14,15]. Thus, early diagnosis of HIV infection 
can benefit the individual, with appropriate initiation of treatment leading to a much improved prognosis [16–20]. 
It is also more cost-effective in both the short [21] and long term with fewer episodes of acute serious illness [22]. 
As HIV infection may have almost no symptoms for many years, testing is the only way to achieve early diagnosis, 
enabling early referral for treatment and care. 
 
It is now well recognised that antiretroviral therapy reduces an individual’s infectivity by lowering concentrations of 
virus in genital secretions to levels below those at which transmission is likely to occur [23]. 
Mother-to-child transmission is drastically reduced by initiating antiretroviral therapy for pregnant women who are 
diagnosed with HIV before or during pregnancy, and consequently many European countries include routine HIV 
testing in antenatal screening programmes [24,25]. 
There is also evidence that people diagnosed with HIV take great care not to transmit the infection. HIV-positive 
individuals have been found to have more consistent condom use than those who are HIV-negative, and decreased 
levels of unprotected sex have been reported following an HIV diagnosis [26]. HIV-infected men who have sex 
with men have reported significantly lower rates of unprotected sex with partners of different or unknown HIV 
status than with partners of the same status [27], and an HIV diagnosis during the period of primary infection has 
been shown to motivate the majority of men to reduce their risky behaviours substantially [28]. 
Early diagnosis of HIV thus has great benefits for both the individual and the community. Increasing the proportion 
of people with HIV who receive an early diagnosis is a critical public health priority. 
1.3 Core principles for national HIV testing strategies and 
programmes 
It is recognised that the countries of Europe currently vary widely in their political and social approaches to HIV but 
to ensure that a national HIV testing strategy takes an ethical approach based on human rights, countries need to 
adhere to the following principles. As far as possible, these principles are based on evidence, but in some cases 
they are aspirational and have their basis in accepted best practice and expert consensus. 
HIV testing should be voluntary, confidential and undertaken with 
informed consent 
 
A national HIV testing strategy must primarily serve the needs of those who are infected and as yet undiagnosed. 
People must be able to choose to test for their own benefit rather than be coerced or compelled, even where this 
would be deemed to be in the interests of the wider public health. Their decision to test must be based on 
informed consent. 
There should be easy access to voluntary testing for everyone and special efforts need to be made to ensure 
this for groups most at risk for, and vulnerable to, HIV. These will include people who are hidden or 
marginalised in society for whom access to testing should be encouraged without coercion or breach of 
confidentiality. 
People diagnosed early may also be less likely to transmit the virus to others because of both lower infectivity 
when treated and changes in sexual and drug injecting behaviour. Mother-to-child transmission can be 
effectively prevented by HIV testing and treatment of pregnant women. 
There is strong evidence that earlier treatment reduces morbidity and mortality, but many people with HIV 
remain undiagnosed until late in the course of infection. 
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Confidentiality is a fundamental principle of all healthcare and is of particular importance to HIV testing. Fear of a 
breach of confidentiality will deter individuals from seeking HIV testing or accepting it when it is offered [29–31]. 
In Europe, the communities most affected by HIV are socially marginalised and this, combined with HIV-related 
stigma, can create a barrier to HIV testing [32,33]. Services therefore need to be designed in such a way that 
members of those communities can come forward without fear of reprisal or blame. 
This is best achieved by making HIV testing available in a wide range of settings, both medical and non-medical, 
delivered by appropriately trained and competent staff. There should be clear referral pathways to, and support 
from, HIV specialist services. 
Ensure access to treatment, care and prevention services 
 
Treatment is defined as treatment for HIV infection itself, treatment for conditions arising from it and treatment for 
conditions which place people at risk of HIV infection (e.g. drug dependencies). It should be complemented by 
access to psychosocial care and support, and prevention services.  
This principle should apply to all population groups including undocumented migrants or migrants of uncertain 
residency status for whom access to healthcare may be limited by existing policies. 
Where it does not apply under current structures, consideration should be given to ways of making such treatment 
accessible, in line with the 2001 UNGASS Declaration of Commitment on HIV/AIDS and the 2004 Dublin Declaration 
on Partnership to Fight HIV/AIDS in Europe and Central Asia which commit EU Member States to providing 
universal access to comprehensive HIV prevention, treatment, care and support programmes by 2010. 
Show political commitment 
 
Increasing the proportion of people with HIV who receive an early diagnosis is a public health priority. This needs 
to be reflected in national health strategies, legislative programmes and spending plans. Leadership is needed to 
motivate and support decision makers at all levels, to provide incentives for widening the reach of voluntary 
confidential testing programmes and ensuring they are appropriately targeted, and to overcome structural and 
attitudinal barriers. 
Adequate financial resources need to be provided for HIV testing programmes as well as for HIV surveillance, 
prevention, treatment, care and support services. 
Reduce stigma 
 
HIV and the behaviours most commonly associated with its transmission can be highly stigmatised; this is a 
significant barrier to HIV testing and can operate on an individual level and on structural or institutional levels such 
as in the workplace or in healthcare services [32–34]. 
Public education campaigns have been shown to increase HIV testing rates [35,36] and these increases may in 
part be the result of decreasing the stigmatisation of HIV. It is important to dispel myths about the ways in which 
the virus is transmitted, to promote HIV testing as a normal part of healthcare and to emphasise the advances in 
treatment which mean that HIV infection is no longer a fatal illness but a chronic condition. Visible and high-level 
support from opinion formers, including politicians, community leaders and celebrities, as well as supportive and 
accurate coverage in the media, can all be used to raise awareness. 
The engagement of healthcare workers is central to any HIV testing strategy. A proactive approach to HIV testing 
on the part of healthcare workers has a positive influence on the individual’s decision to accept the offer of a test 
[37]. However, HIV-related prejudice among healthcare workers in some countries has been described [38,39] and 
efforts need to be made to minimise the impact of this on HIV testing rates. 
The stigma that is still attached to HIV is a barrier to testing, especially among communities that are 
themselves stigmatised and among healthcare workers. ’Normalising’ testing, e.g. making the process more like 
that for other screening and diagnostic tests, can help counter this, although testing must remain voluntary. 
Government priority for the HIV testing programme is required in order to achieve impact. This needs to be 
supported by financial investment, which should be monitored to ensure that funds are used in a cost-effective 
way. 
The single biggest benefit of HIV testing is access to treatment. Providing universal access to treatment and 
care, prevention and support services, with clear referral pathways, must be a cornerstone of national HIV 
testing strategies. 
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Remove legal and financial barriers 
 
Disincentives to HIV testing may include laws which criminalise sex between men, sex work and use of illicit drugs, 
as they may require disclosure of illegal acts [40]. In particular, criminal prosecutions for HIV transmission or 
exposure are unlikely to serve the interests of public health and may create a situation where remaining 
undiagnosed constitutes a defence for the individual. 
The following measures may be considered: 
• Changes in law, and/or how existing law is applied, relating to groups at higher risk of HIV to create an 
environment in which they are able to come forward for testing without fear of reprisal. 
• Changes in law to decriminalise homosexual behaviour. 
• Anti-discrimination legislation to protect those diagnosed with HIV and minority groups most at risk of HIV.  
• Policies or legislation to prevent mandatory testing or testing without consent, for any group in any setting, 
such as in prisons or for migrants seeking to enter the country [41] (although there are specific situations 
where HIV testing is necessary to fulfil certain functions such as for blood and organ donors, and in relation 
to possible professional exposure). 
Governments need to ensure that healthcare systems are set up in such a way that no one is denied treatment on 
grounds of inability to pay for it. This may require rethinking models and conditions of access to healthcare in 
some countries. Similarly, no one should be denied an HIV test because they cannot afford to pay for it. 
Make access to HIV testing an integral part of national strategies  
 
The relationship between the presence of sexually transmitted infections (STI) and increased probability of HIV 
infection is well documented, as is the similarity of transmission routes [42,43]. The IUSTI/WHO Europe 2008 
European Guideline on HIV testing recommends that all individuals who seek evaluation and treatment in STI 
clinics should be offered an HIV test [3]. 
It is now widely accepted that antenatal screening programmes should include universal HIV testing and many 
European countries have adopted this approach [44] There have been calls for strategies for the management of 
individuals with tuberculosis, viral hepatitis and lymphoma to include a routine offer of HIV testing, based on the 
prevalence of these conditions in people with HIV and on the need to manage them differently in people with HIV 
co-infection [45,46]. 
National strategies concerning behaviours or settings which increase the risk of HIV transmission or population 
groups at higher risk of HIV, such as those on the management of illicit drug use, sex work, or healthcare in 
prisons, can provide opportunities to increase the reach of effectively targeted HIV testing. Where HIV prevalence 
in prisons is known or estimated to be high, access to HIV testing for prisoners should be an essential component 
of HIV testing programmes. Care should be taken to ensure this is always undertaken with informed consent and 
without coercion or breach of confidentiality, in line with the core principles of this guidance and 
UNODC/UNAIDS/WHO recommendations [47]. 
Wherever possible, testing for STI and viral hepatitis should be offered alongside HIV testing for population groups 
at higher risk. 
  
Any national strategies for the prevention and treatment of HIV, other sexually transmitted infections, viral 
hepatitis, tuberculosis and other HIV indicator diseases must include HIV testing, with appropriate targeting, as 
a key element. Opportunities to increase access to, and uptake of, voluntary confidential HIV testing should 
also be identified within other relevant national strategies, such as those targeting pregnant women, drug use, 
sex work or healthcare in prisons. 
Testing strategies should find ways to overcome legal and financial disincentives to testing. Such barriers may 
include policies of criminal prosecution for HIV transmission, or the requirement to pay for treatment where this 
is unaffordable. With the exception of mandatory testing of blood and tissue donations anti-discrimination 
legislation and policies to prevent mandatory testing for any group in any setting should be considered. 
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Develop and implement an HIV testing strategy with the participation 
of stakeholders 
 
It is essential to use the best available evidence, knowledge and epidemiological information to help clarify 
strategic aims and objectives, and to set priorities. Where evidence is lacking, structures need to be put in place to 
improve it. More information on evidence to support strategy development and monitoring is provided in Sections 
2.1 and 3. 
Use available information about HIV and related issues nationally and locally to help clarify what needs to be 
achieved and where the priorities lie. Encapsulate this in a set of strategic aims and objectives, so that 
everyone involved or affected has a shared understanding. Developing the strategy requires the participation of 
all major stakeholders in order to build a coalition around shared objectives. These include people living with 
HIV, representatives of communities most affected, civil society and prevention agencies, professionals with 
expertise in HIV testing and others with a role in implementing the strategy. 
The implementation and delivery of the strategy will also need to involve all these groups, not only the 
healthcare professionals. When setting the objectives, identify how progress against them will be monitored. 
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2 Developing a national HIV testing strategy 
Just as every country in Europe is socially and culturally distinct, so is every country’s HIV epidemic. A prerequisite 
for any successful HIV testing strategy is good quality information. It is important to form as accurate a picture of 
the epidemic as possible and to identify barriers to, and facilitators for, testing. This information will determine the 
most important population groups to target and the most suitable sites for HIV testing. This in turn will help to 
identify the measures that need to be taken to implement the strategy, such as financial resourcing, service 
reorganisation, staff training and awareness-raising among the target populations. 
2.1 Whom to test? 
 
The aim of surveillance is to build an understanding of the epidemic and time trends at local, regional and national 
level and among population groups in order to inform policy and intervention efforts. The reporting of new 
diagnoses of HIV by clinicians and laboratories forms the basis of the understanding of the local and national 
epidemic in most European countries. These data should be supplemented by other surveillance systems and 
surveys to provide greater insights into the epidemic within the general population and higher risk groups. The 
World Health Organization has produced comprehensive guidance on how to plan surveillance of HIV 
seroprevalence and behavioural risks [48], and a framework for behavioural surveillance is being developed for 
Europe by the European Centre for Disease Prevention and Control [49]. 
In most European countries, the HIV epidemic is concentrated in three sub-populations [7]: men who have sex 
with men, migrants (especially those from high HIV prevalence countries) and injecting drug users. Additional 
groups at higher risk have been identified in Europe, for example, prisoners, sex workers, and people with sexually 
transmitted infections and other indicator diseases [50]. 
It is important to consider ways of extending HIV testing to reach the additional risk groups identified within each 
country based on national data. 
The groups at highest risk of HIV infection are also often disenfranchised and stigmatised, and as a result may not 
access healthcare services or disclose their risk behaviours when they do. Barriers to HIV testing exist for many of 
these groups and such barriers need to be understood in different countries and for different sub-populations, with 
more research being conducted as necessary. Where research on barriers has been conducted and services 
adapted accordingly, the acceptability of HIV testing for the sub-population concerned increases [32,33]. 
Although HIV infection in Europe is mainly found in the sub-populations described above, it is also found in the 
general population. Rates of HIV infection among women attending antenatal care can provide a proxy for the HIV 
prevalence in the general population as well as identify women at greatest risk when this information is stratified 
by risk and other demographic information. Surveys about HIV risk in the general population are also useful for 
comparisons of risk between the sub-populations believed to be at higher risk and the general population [48]. 
Routinely collected data on HIV-positive individuals are also important to ensure that diagnosed individuals are 
seen and receiving optimal care. Data from healthcare services other than those that specialise in HIV care, for 
example sexual health, viral hepatitis and tuberculosis, as well as blood donation [51], may also be useful in 
building a picture of the national epidemic and access to HIV testing and care. Where resources are limited, 
sentinel surveillance from a representative sample of HIV-positive individuals and/or the healthcare services they 
attend may be suitable. 
Know your epidemic and identify groups most at risk. An effective national approach to HIV testing will rely on 
having an understanding of the epidemic at local and national level. Testing programmes should aim to reach 
those at risk of infection and to prioritise those at highest risk. 
Identify and review available surveillance and other relevant data, including information on undiagnosed HIV 
and late diagnosis, to build an understanding of the epidemic and time trends at local, regional and national 
level. Some groups are especially at risk for HIV, including men who have sex with men, injecting drug users, 
migrants (especially those from countries with higher prevalence), the sexual partners of individuals in all of 
these groups and the children of HIV-positive mothers. Such sub-populations and/or their risk are often hidden 
and stigmatised. Special surveys will need to be conducted to find out about the levels of HIV among such 
groups, their rates of HIV testing, and relevant knowledge, attitudes and behaviour, in order to inform 
interventions to increase their uptake of HIV testing. 
Finally, supplementary data on other sexually transmitted infections, sexual and drug injecting behaviours in 
the general populations, as well as groups at higher risk of HIV, should also be reviewed. 
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Estimating the proportion of people with HIV who are unaware of their infection (the ‘undiagnosed fraction’) is 
important because it allows the scale of the problem to be determined and the success of any programme to be 
monitored over time. There are many approaches to calculating this measure, each with its own advantages and 
disadvantages. Measuring late presentation using CD4 count at diagnosis is also an important measure of delays in 
access to testing and care. Late presentation is associated with higher morbidity and short-term mortality [52]. 
More detailed information on key epidemiological indicators is provided in Section 3 (Monitoring and evaluation). 
2.2 Where to test? 
Consider logistics 
 
Increasing the reach of HIV testing, improving its targeting and providing it in new ways is likely to require 
improvements to existing HIV testing services, changes to other healthcare services and the introduction of 
completely new services. Examples of this would be introducing the routine offer of an HIV test in a range of 
healthcare settings or the establishment of outreach HIV testing services for marginalised groups in community 
settings. The feasibility and appropriateness of such approaches should be assessed and plans will need to be 
developed to overcome barriers, or to work within existing constraints. Such barriers or constraints may include, 
for example, the restriction of HIV testing provision to particular professional groups or settings. It will also be 
necessary to involve those whose commitment and participation will be necessary for success; both civil society 
and professional groups. 
Service planning needs to address the requirements of privacy, confidentiality, the option of anonymity, safety, test 
accuracy and other quality considerations. It should ensure services are appropriately targeted and that they meet 
the needs of the groups they target. Policies or measures which contradict the core principles of this HIV testing 
guidance (Section 1.3) should be reviewed and amended, for example those with implications for testing prisoners 
or migrants. 
The availability of specialist HIV treatment services, as well as other relevant healthcare, counselling and support, 
should be ensured for those who receive a positive HIV test result and, where needed, those who receive a 
negative HIV test result. Adequate care pathways should be in place to ensure prompt and appropriate referral and 
access to such services for all who need them (see Section 2.5). 
Make testing available in a variety of settings 
 
Barriers at the institutional level may hinder efforts to expand HIV testing, including failure to appropriately target 
the populations most at risk [53] and to provide conveniently located testing sites [54,55]. Offering HIV testing in 
medical and non-medical settings, in co-operation with non-governmental organisations, including outside normal 
working hours, can facilitate access and uptake. 
It is therefore important to work with affected communities to identify both medical and non-medical settings used 
by members of the populations most at risk. A systematic approach can be taken to identify specific populations, 
which settings can be used to reach them, the advantages and disadvantages of each, their relative cost benefits 
and other considerations. 
Whatever the setting, HIV testing programmes should be sensitive and responsive to the needs of the population, 
and should be established with the involvement of the relevant target group(s) [32,33]. 
 
Identify action needed to establish new services or change practice in existing healthcare settings or 
community services. Evaluate whether regulations that may act as obstacles to testing in community settings, 
including use of point-of-care tests or the requirement for tests to be performed only by specific professionals, 
could be relaxed without compromising testing quality. 
Use knowledge of the epidemic and who is at highest risk to make informed decisions about where to offer HIV 
testing. Also consider any available data about who is currently accessing HIV testing in which settings. 
Because of the diversity of needs and the barriers to testing, a range of services should be offered in order to 
maximise access. 
Plan how the HIV testing programme will be implemented and tackle logistical challenges. These may include 
how the healthcare system is delivered, whether there is access to free healthcare, the preparedness of 
community services, counselling and support, how to ensure care pathways are in place for access to HIV 
treatment, and how confidentiality can be assured. 
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Dedicated HIV testing services, to provide easy and safe access to HIV testing 
alone or combined w ith other tests 
Services set up specifically to provide HIV testing for those who wish to have a test should be maintained or 
expanded, ensuring they are designed to meet the needs of the populations they are intended to serve. Depending 
on the healthcare system and how HIV care has developed in each country, dedicated HIV testing services may be 
provided within relevant specialist settings such as sexual health or infectious disease clinics or exist on a stand-
alone basis. It is important to ensure that such services are welcoming and culturally appropriate for the population 
groups which need to use them, including young people, gay men and migrants, and that access to them is not 
hindered by concerns of confidentiality or cost. The option of anonymous testing should be available. Language 
services, such as interpreters or multilingual staff, should be provided for migrant populations where needed. 
It is likely to be more cost-effective, and convenient for the individual being tested, if the HIV test can be offered 
in combination with other tests. 
Settings where HIV testing should be universally offered 
In certain healthcare settings, outlined below, it is beneficial to offer and recommend an HIV test to all those 
attending (a ‘universal offer’). As with HIV testing in other contexts, HIV testing when universally offered still 
requires informed consent (see Section 2.4 for more on informed consent). However, it is not usually necessary to 
conduct a full risk assessment of sexual or drug-using practices, except when this is relevant to the specific service, 
e.g. STI services. 
Services for people at high risk, such as STI services or services for injecting drug users 
Sexual behaviour is the most common route of transmission of HIV infection. Services which diagnose and treat 
STIs should therefore routinely offer HIV testing. Risk-based HIV testing has been found to miss a significant 
proportion of HIV infections [56,57]. The WHO European Regional Office and guidelines issued by International 
Union against Sexually Transmitted Infections (IUSTI) recommend the routine offer of HIV testing to anyone 
diagnosed with an STI [2,3]. 
Services for injecting drug users, including drug treatment, substitution and needle and syringe programmes, present 
an opportunity to provide HIV testing. Injecting drug users are a particularly vulnerable population with high levels of 
physical and psychological illness and often chaotic lifestyles [58]. Every country in the European Union offers needle 
and syringe programmes and all countries include some form of drug treatment programme [59]. 
Antenatal services, where early intervention can prevent onward transmission of HIV 
Antiretroviral therapy during pregnancy is extremely effective in preventing vertical transmission of HIV [24,25]. 
Antenatal HIV screening programmes, which enable access to such therapy, are a good example of how a clearly 
defined and well implemented HIV testing strategy can significantly reduce transmissions. 
While many European countries currently have policies to routinely offer HIV testing to pregnant women [44], this 
may not be reflected in practice and some women may remain undiagnosed. A universal offer of HIV testing is 
recommended in a number of European countries; sometimes integrated with screening for other STIs or blood-
borne viruses. Where instituted, this policy has resulted in substantial increases in rates of testing [44]. It is 
supported by evidence that risk-based antenatal testing misses a substantial proportion of HIV-infected women 
reporting no risk factors for HIV [60,61]. 
Where countries have introduced targets for HIV testing and the offer of an HIV test in antenatal care has become 
routine, the uptake of testing by women has dramatically increased, indicating that the test offer is highly 
acceptable to both pregnant women and staff [62]. It is noteworthy that, even in countries where it is rarely 
performed, women find the offer of antenatal HIV screening acceptable [63]. 
Women who have not been offered an HIV test during pregnancy or who first present to services when already in 
labour, should be offered an HIV test during labour [24]. 
Services which undertake the clinical diagnosis and management of HIV indicator conditions 
Healthcare services for people with diseases associated with HIV infection (see Appendix B) are likely to serve a 
population with a higher prevalence of HIV, ranging from three per cent of those with perinatal listeriosis to 94 per 
cent of those with cryptococcal meningitis [45]. The European AIDS Clinical Society has developed a list of 
indicator diseases that are associated with a higher than one per cent incidence of HIV infection [45] and 
recommends a routine offer of HIV testing for all those who present with these conditions (see Appendix B). 
Including the HIV test as a routine investigation when people with clinical indicator conditions associated with HIV 
seek healthcare is likely to increase testing rates and reduce late diagnoses [45]. 
There are, however, barriers to HIV testing for people presenting with certain conditions associated with HIV 
infection, including stress related to the initial diagnosis, such as tuberculosis, or fear of added stigma of a second 
illness [32]. Including a routine offer of HIV testing in healthcare services for the clinical diagnosis and 
management of tuberculosis will therefore help to normalise the test for patients and staff and may contribute to 
the detection of HIV in those who would otherwise not have been considered at risk [64]. 
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Settings where undiagnosed HIV prevalence is known or estimated to be high 
Such settings will vary between countries, and between areas within countries, depending on the local epidemic, 
the healthcare delivery system and which services are used by populations most at risk of HIV. They may include 
specific types of setting more likely to be attended by those at higher risk, including prisons, termination of 
pregnancy services, services for sex workers and youth services. They may also include general healthcare settings 
such as primary care, emergency departments and medical admissions units in geographical areas where HIV 
prevalence is high. 
Areas with a high level of diagnosed HIV prevalence are also likely to have a high level of undiagnosed prevalence. 
This principle underpins the recommendation in UK guidelines to expand HIV testing in local areas of high 
diagnosed prevalence, specifically in general practice and general medical admissions to hospital. Research in the 
United States indicates that testing in general healthcare settings may be cost-effective where there is a high 
(greater than 1 per 1000 population) undiagnosed prevalence of HIV [65]. 
All other healthcare settings, where people should be able to request testing or 
where professionals should be ready to offer it and be vigilant to when it is needed 
People should be able to receive an HIV test when they request it in any general medical setting, such as primary 
care, sexual and reproductive health services and youth clinics. 
Professionals in all healthcare settings should also be vigilant to the possibility of undiagnosed HIV infection and 
aware of the risk factors and clinical indicators for HIV. They should be ready and able to offer HIV testing when it 
is needed. 
Testing sites in the community, including outreach services, to reach people at 
higher risk of HIV who may be hidden or marginalised and not in touch w ith 
traditional healthcare services 
Testing in the community is a broad term that encompasses services providing HIV testing, usually for specified 
groups at higher risk of HIV, in non-traditional or non-medical settings such as Gay Pride events, mobile testing 
buses or homeless shelters. It may be provided as a dedicated HIV testing service or as part of broader range of 
services (health or otherwise) for the target group. 
Testing in community settings may reach greater numbers of people at high risk of HIV. For example, higher risk 
injecting drug users who do not attend drug treatment programmes may be reached through outreach services 
such as needle exchange programmes. HIV testing services for migrants from areas of high HIV prevalence can be 
grounded in outreach and community mobilisation projects, building on existing structures and partnerships [66]. 
To overcome barriers to access it is important to ensure that the features of such services, for example their 
location and opening hours, are adapted to the needs and lifestyles of the groups they aim to reach. 
 
When developing community-based HIV testing services it is also important to engage with civil society 
organisations that serve groups at higher risk of HIV infection [32,33] and to ensure good clinical governance of 
community testing services, with clear referral pathways for confirmation of reactive results and access to 
treatment, care, counselling and support, and to prevention services.  
2.3 When to test? 
Provide guidance on testing frequency 
 
Repeat HIV testing may assist early detection of HIV infection in at-risk populations and individuals with repeated 
episodes of unsafe behaviour. However, it is not clear whether repeat negative tests reinforce risk behaviour or 
whether repeat testers are more likely to correctly identify and disclose risk behaviours. Retrospective studies have 
characterised repeat testers as more likely to engage in high risk behaviour between tests; this is especially true 
for men who have sex with men [68–72]. Evidence-based counselling, with continuous quality assurance, is a 
measure that may be used to counteract the potential negative effects of repeat testing on risk behaviour. 
More frequent testing is advisable for people who have ongoing exposure to high risk. For example, some 
countries recommend that men who have sex with men should be tested annually, or more often depending on 
sexual behaviour. Current guidance from the European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) recommends regularly offering tests to injecting drug users at least once every 6 to 12 months [67]. 
Such services should be established with the involvement of the targeted sub-populations. 
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Where guidance on repeat testing for groups at higher risk of HIV exists, this is based on expert advice, accepted 
good practice and modelling studies. The United States, Australia, France, Norway and the UK recommend annual 
testing of all individuals in specified groups at higher risk. 
The cost-effectiveness of repeat testing of groups at higher risk will depend on the HIV incidence and prevalence 
within the sub-population. Economic modelling has not found annual testing to be cost-effective even in 
populations with high (3 per cent) prevalence [73]. However, a French evaluation of HIV testing strategies found 
both a one-off HIV test in the general population and regular HIV testing in populations at high risk and in areas of 
high prevalence to be cost-effective [74]. 
2.4 How to test? 
Raise public awareness 
 
Ensuring that accurate information is available about HIV, its transmission routes, its prognosis and how 
treatments affect it, should be part of a national HIV testing strategy. A range of communication channels should 
be used, including local healthcare professionals and community-based organisations as well as traditional and 
electronic media, and communication strategies should be adopted to reach the most-at-risk populations [75]. 
Such interventions need to be tailored to needs and culturally appropriate for their target audiences. 
Responsible media reporting of HIV should be promoted and, where possible, people in the public eye can assist in 
preparing the public to consider the benefits of testing for HIV. It is also useful to consider implementing targeted 
public awareness campaigns aimed at populations most at risk of HIV [36,75,76]. 
Information efforts need to be maintained over time in order to have a sustained impact as, although short-term 
media campaigns have resulted in significant immediate increases in HIV testing, a sustained impact is not 
achieved once a campaign ends [36]. 
Ensure confidentiality 
 
The importance of confidentiality and how to ensure it is highlighted in the WHO European Region policy 
framework on scaling up HIV testing and counselling [2] and the WHO/UNAIDS guidance on provider-initiated 
testing [4]. 
In migrant populations confidentiality concerns are particularly relevant [36]. A fear frequently observed in migrant 
populations is that an HIV diagnosis will have negative consequences for immigration or asylum applications 
[29,30,37,77]. Fear of the negative social consequences of a positive diagnosis (stigma, discrimination, rejection) 
has been highlighted as more important than fear of death or illness among all populations, including migrants and 
men who have sex with men [34]. 
 
There is evidence that individuals choosing anonymous testing have a high burden of HIV [78]. This approach can 
remove a barrier to testing for disenfranchised populations such as uninsured individuals, non-residents, 
undocumented migrants, injecting drug users, men who have sex with men and prisoners, especially when 
provided free of charge. 
  
HIV testing should always be offered and discussed in privacy. The option of anonymous testing should be 
available. 
Confidentiality is a fundamental principle of all healthcare but because of the stigma attached to HIV and the 
behaviours through which it may be transmitted, it is critically important for HIV testing. Relevant professional 
guidance and national legal requirements should be followed. A lack of confidence in confidentiality among 
people at risk may act as a barrier to accessing HIV testing services. 
Clear policies on confidentiality, and publicity about the policies in settings providing testing, can help to 
overcome this barrier. 
To seek and accept HIV testing, the public, and especially groups at higher risk of HIV, need to understand its 
benefits. A strategic approach to communication is needed, using a range of different channels. Visible and 
high-level support from opinion formers, including politicians, community leaders and celebrities, and 
supportive and accurate coverage in the media, can all be used to raise awareness. 
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Raise professional awareness and train the workforce 
 
Important barriers to HIV testing identified at the provider and institutional level include lack of staff training and 
the perception that HIV testing can only be offered and performed by specialists. Education and training are 
therefore needed to ensure that healthcare and other relevant workers are able to offer the test appropriately and 
for the right reasons, and that people at risk of HIV are made to feel able to come forward for testing or to accept 
the offer of a test. HIV testing should be part of the general medical curriculum for all doctors in training. 
Research into patients’ barriers to testing has highlighted the importance of the healthcare worker’s 
recommendation in influencing their decision to test [77,79]: making the test offer more routine and the process 
more like that for other diagnostic tests will contribute to a reduction in HIV stigma [63,80]. 
To motivate healthcare workers to offer the test, it is important that they understand the benefits of HIV testing. Staff 
training should include a mix of information and skills development which includes details of the national HIV epidemic, 
and relevant guidance on consent and confidentiality. Training should be audited as part of good clinical governance, 
and attendees at services offering HIV testing need to be made aware that staff are appropriately trained. 
The requirement to conduct a full risk assessment of sexual or drug using practices has been highlighted as a 
barrier to HIV testing. This is because many healthcare professionals who do not specialise in HIV or sexual health 
are unwilling to conduct risk assessments for fear of embarrassing or offending people who do not fit the usual HIV 
risk profile, even where such assessments have been recommended as good practice. This often results in the test 
not being offered [77,81]. However, in some settings where an HIV test is universally offered, such a risk 
assessment is not usually necessary (see Sections 2.2 and 2.4). 
Pre-test discussion 
 
As with any medical test or investigation, people need to be able to make an informed decision about whether to 
undergo an HIV test. The model of pre-test counselling traditionally used included an in-depth discussion about an 
individual’s risk behaviour and an assessment of their likelihood of being infected. However, this can be a barrier to 
HIV testing if those offering the test feel unable to carry out such a risk assessment due to lack of appropriate 
training, personal discomfort with discussing sexual behaviour or drug use, or fear of offending or embarrassing 
the person offered testing. 
Pre- and post-test ‘counselling’ requirements can be seen by health professionals as a barrier to HIV testing [82–
85], implying the need for specialist counselling skills or the presence of a qualified counsellor. To reduce this 
barrier and to help normalise the HIV test, there has been a move away from in-depth pre-test counselling towards 
shorter pre-test discussion [3]. Brief pre-test discussion (sometimes referred to as 'pre-test information') has been 
shown to be acceptable to people taking the HIV test and is not detrimental to testing uptake [86]. This covers the 
essentials such as the voluntary nature of the test, the benefits of testing, the practical arrangements for taking 
the test and details of how the result will be given. 
Removing the need for written consent has also been shown to be effective in increasing rates of testing [87,88]. 
It is helpful to provide further information for those who need it about other aspects of HIV infection, as lack of 
information can be a barrier to testing [37]. 
For those offered a test on clinical grounds, a detailed sexual history is not required before offering an HIV test, 
nor is it necessary to obtain information about current or previous drug injecting. However, it is important to be 
Brief pre-test discussion, covering the benefits of testing and the practical arrangements for taking the test and 
giving results, has been shown to be acceptable and effective in helping to increase testing uptake. The main 
purpose is to ensure informed consent which should be documented but does not have to include signed 
written consent. This is in line with other medical investigations and is part of the normalisation of HIV testing. 
A detailed sexual or injecting history is not required before offering an HIV test. However, for certain 
individuals, or in settings where sexual health and/or drug use is within the scope of the services, a brief risk 
assessment or more extensive pre-test counselling may be indicated, e.g. in case of continued risk exposure. 
This should always be available and staff should know how to refer to skilled counsellors.  
While activities to raise public awareness will also reach professionals, training can be used to raise their 
awareness and increase their confidence and competence to offer HIV testing. 
HIV testing can be offered by any appropriately trained and skilled healthcare worker, and expanding HIV testing 
will require a wider workforce which is confident and competent to offer it. With appropriate training and quality 
assurance, non-healthcare workers may also offer HIV testing. Members of the workforce need to understand the 
benefits of HIV testing and overcome the barriers which inhibit their ability and willingness to offer it. These 
include lack of confidence in raising the subject, difficulties in talking about sex or stigmatised behaviours, anxiety 
about giving a positive result and discriminatory attitudes towards people at risk or affected by HIV. 
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aware that some people may present with more complex needs. This will require a more in-depth discussion and 
access to high-quality counselling if needed. Such individuals may also benefit from the HIV prevention messages 
that such a discussion covers. 
In some HIV testing services which target the populations most at risk, such as those in the community, a brief risk 
assessment may be a routine part of the pre-test discussion. Such services can be important places for identifying 
individuals with ongoing high risk behaviour and referral should be available to high-quality prevention services, 
counselling and support (see Section 2.5). 
Use appropriate testing technologies 
 
The use of an enzyme-linked immunoassay (EIA) followed by confirmatory Western blot or line-blot assay is 
currently the gold standard minimum laboratory algorithm for diagnosing HIV infection. Preferably, fourth-
generation screening assays that simultaneously test for anti-HIV-1 antibodies and HIV-1 p24 antigen as well as 
anti-HIV-2 antibodies are recommended to be used as serological HIV screening tests [90,91]. For the fourth-
generation tests, a separate confirmatory test for the antigen component of the test is necessary. 
Rapid HIV tests, also known as point of care tests (POCT), may improve HIV testing acceptability and uptake in 
several key settings. These include busy clinical settings, where they can increase uptake of HIV testing when 
offered [92], for example among people who are unwilling to have blood taken, or where an HIV test result is 
needed urgently; and community testing settings serving high-risk populations where traditional venepuncture is 
not possible or where quick turnaround of test results is desirable [93,94]. Rapid testing has been shown to be 
acceptable and feasible in community settings [55,95–100] and has the advantage of increasing the proportion of 
test results that are passed on to testing recipients [101,102]. 
Rapid HIV testing has been shown to be acceptable to women in antenatal screening programmes and may have a 
useful role in labour and delivery settings for women who previously declined standard HIV testing [103]. Rapid 
HIV testing is also increasingly being offered by STI services in some countries as this is preferred by some 
attendees [104,105]. It may also be useful following blood exposure accidents. 
There is conflicting evidence on the acceptability of rapid testing compared with standard testing among injecting 
drug users [106–108]. However, with high rates of failure to return for results of the standard test, rapid testing 
may be useful in ensuring receipt of result and entry into care [109]. 
The performance characteristics of rapid tests differ from those of standard EIA tests and these should be taken 
into account when assessing the suitability of rapid testing for use in any particular setting. Such characteristics 
include specificity, sensitivity, window period and ease of use in the setting. Both saliva and blood tests may be 
used as screening tests, as long as the tests have been issued a CE-mark for the sample material. 
Rapid testing should be quality-assured, with established links to the laboratory. The United States CDC and WHO 
have issued joint quality assurance guidelines for rapid testing which could be used or adapted for quality 
assurance in European countries [89]. 
Always give results 
 
It can take up to two weeks for the result of a standard laboratory HIV test to become available. Therefore, unless 
a rapid HIV test is used with results available at the same visit, an appointment should be made for people to 
receive test results. 
Positive results should always be given in person and preferably by the healthcare worker who performed the test. 
Arrangements need to be made for results to be given face to face, in privacy and with sufficient time for discussion. 
Every effort should be made to ensure that people who have had an HIV test are informed of the result, 
whether positive or negative. When giving positive results, ensure staff are available to provide post-test 
counselling and that links to appropriate HIV treatment and support services are also in place for referral. 
People at high risk of HIV who receive a negative test result may also benefit from counselling and referral to 
appropriate prevention services. 
Identify the HIV tests available and assess their respective benefits for testing in different contexts, including 
rapid (point-of-care) screening tests. Testing technology is constantly evolving and expert advice should be 
sought to keep the choice of tests under regular review. All reactive screening tests (including point of care 
screening tests) should be verified using more specific confirmatory tests in accordance with WHO and 
European guidelines.  
National guidelines for applying a minimum standard of quality assurance for diagnostic testing based on WHO 
and European guidelines are essential to ensure high-quality practice and methodological standardisation and 
reliability [3,89]. 
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People found to be HIV-positive should be given details of local specialist services and, prior to the result being 
given, there need to be clear pathways in place for onward referral. More detailed post-test discussion (including 
assessment of disease stage, consideration of treatment, partner notification and need for psychosocial support) 
should usually be performed by the HIV specialist team and those diagnosed with HIV should be fully informed 
about this process (see also Section 2.5). 
It may be possible to provide negative HIV test results using methods such as telephone appointment, SMS 
message or post if this will help to streamline the process [110] and to reduce the number of occasions on which 
patients do not return for test results [111–113]. However, giving a negative result in person provides an 
opportunity to engage in sexual health promotion and offer HIV prevention messages especially for those at higher 
risk of infection. 
2.5 Ensuring access to HIV treatment, care and prevention 
Access to antiretroviral therapy 
 
The 2001 UNGASS Declaration of Commitment on HIV/AIDS and the 2004 Dublin Declaration on Partnership to 
Fight HIV/AIDS in Europe and Central Asia commit EU Member States to providing universal access to 
comprehensive HIV prevention, treatment, care and support programmes by 2010. 
Referral pathways should be in place from all HIV testing sites to ensure that people receive a specialist 
consultation promptly after receiving a positive HIV test result. This consultation should include an assessment of 
when to start antiretroviral therapy and needs for other health and social care and support. 
Access to care is important to ensure that diagnosed individuals benefit from antiretroviral therapy and from other 
health, social care and support services. It is recommended that HIV testing strategies include a requirement for 
prompt access to specialist care. For example, UK guidelines recommend that an individual testing HIV-positive for 
the first time be seen by a specialist at the earliest possible opportunity, preferably within 48 hours and certainly 
within two weeks of receiving the result [114]. It is therefore important to ensure that access to treatment is not 
hindered by structural factors such as healthcare system organisation or legislation that restricts access for 
populations at higher risk, in particular migrant communities. 
Where HIV testing is carried out in non-traditional settings, such as acute care settings or community testing sites, 
strong links to HIV specialist services, including dedicated HIV counsellors or HIV clinic appointments, may 
facilitate entry into HIV care. 
Access to psychosocial support and prevention services 
 
Services performing HIV testing should have well established links with providers of psychosocial support in order 
to ensure referral is possible without delay. Appropriately trained personnel from a variety of organisations (e.g. 
community organisations, social services teams) may play a useful role in providing this. 
The fact that many people with a newly diagnosed HIV infection are migrants creates particular counselling and 
support needs, and special efforts need to be made to overcome language and cultural barriers for these 
populations. 
 
This includes strategies for partner contact tracing and partner referral (also known as partner notification) as well 
as counselling and support for behaviour to prevent transmission to sexual and/or drug using partners [115–117]. 
Strategies to encourage regular testing of partners initially found HIV-negative should also be addressed. 
 
Such counselling needs to be evidence-based, provided by those with appropriate skills and training and subject to 
quality assurance. 
For people who test negative, referral to counselling and support for HIV prevention should also be available 
where there is significant ongoing risk of exposure or upon request. 
For people who test positive, referral to specialist care should include access to support for the prevention of 
further transmission of HIV.  
Psychosocial support should be immediately accessible following a positive test result. 
It is essential for all HIV testing programmes to have clear mechanisms to ensure that people who test positive 
are integrated into HIV treatment and care. There should be universal access to antiretroviral therapy across 
Europe. Inability to afford the cost should not prevent access to treatment, and solutions need to be found to 
overcome this barrier to universal access. 
 
 
 
 
HIV testing: increasing uptake and effectiveness in the European Union  GUIDANCE REPORT 
 
 
 
14 
 
 
 
3 Monitoring and evaluation 
 
The monitoring of an HIV testing programme refers to the ongoing collection of data which can be examined at 
any point in the programme and used to determine or inform changes as time progresses. Evaluation refers to the 
systematic analysis of data collected from the programme until a set time point has been reached. The information 
collected should be informed by, and closely reflect, the aims and objectives of the HIV testing programme so that 
it becomes an integral part of the performance management of the programme. Data from M&E systems should be 
used in the quality assurance and quality improvement of HIV testing (WHO, in press). Robust M&E strategies will 
therefore ensure that the HIV testing programme can evolve, develop and remain fit for purpose. 
Monitoring and evaluation relies upon the collection, analysis and interpretation of good quality, standardised data 
and the timely dissemination of results to key stakeholders. Ideally, an M&E framework should be developed 
during the planning stages of an HIV testing programme addressing the following: how the data systems will 
assess programme objectives; how data will be collected; what indicators will be used; who will be responsible for 
data collection; and how data will be disseminated. 
The information will need to be gathered from a range of sources and settings and particular consideration should 
be given to using data collection systems which are already in place. However, lack of data is not a reason to delay 
developing and implementing a programme to increase uptake of testing. A strategy for improving HIV testing 
should be based on the best available evidence and expert consensus and include plans for the development of 
new data systems and/or surveys. 
3.1 Monitoring and evaluation at the national and 
international level 
Indicators are defined measures which are formed from data collected as part of the monitoring and evaluation. 
The selection of indicators will need to be considered before the implementation of the programme and wherever 
possible build on current measures that are being collected. The indicators must be adequate and appropriate to 
monitor and evaluate an HIV testing programme, but at the same time not overburden front-line staff. 
Using indicators at the national level which are consistent with those from other countries enables a comparison of 
the situation at an international level. This allows countries to share knowledge on strategies that have worked and 
compare the means of programmes’ successful implementation. A number of international documents provide core 
indicators for M&E of HIV programmes: 
• The United Nations General Assembly Special Session on HIV/AIDS (UNGASS) core indicators (UNAIDS, 
2009) [118] 
• Implementing the Dublin Declaration on Partnership to fight HIV/AIDS in Europe and Central Asia (ECDC, 
2010) [1] 
• WHO Handbook for improving HIV testing and Counselling Services (WHO, in press) [119] 
• The WHO Guide to Monitoring and Evaluating National HIV Testing and Counselling Programmes (WHO, in 
press) [120] 
• ECDC Mapping of HIV/STI behavioural surveillance (ECDC, 2009) [121]. 
In developing and selecting indicators, it may be helpful to divide those indicators that measure input (e.g. 
infrastructure, financial resources available, policies), process (e.g. human resources, training, adequate and 
appropriate tests available), outputs (e.g. coverage of programme, number of people approached), outcomes (e.g. 
Monitoring and evaluation (M&E) is an essential component of an HIV testing programme and ensures that the 
programme is fit for purpose and provides high-quality HIV testing. 
The process relies on the collection of good quality data and timely dissemination of results to key 
stakeholders. A well designed M&E system will inform policies, improve the quality and effectiveness of 
interventions and therefore guide future allocation of resources. National surveillance data, including new 
diagnoses, the proportion of individuals who present late and an estimate of the number of undiagnosed 
infections, are important for monitoring the impact of a programme. Expanding testing in new settings will 
require robust M&E to ensure high-quality HIV testing reaches the populations most at risk. 
The success of local interventions to promote HIV testing can be assessed according to five criteria: Feasibility; 
Acceptability; effectiveness and Cost-effectiveness; Target populations are reached; and Sustainability (FACTS). 
Clear, well defined and measurable indicators can assist in monitoring these criteria and provide a standard 
method of reporting findings at local, national and international levels. 
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number of tests undertaken) and impact (e.g. reduction in number of undiagnosed infections or proportion of HIV 
infections diagnosed late). These categories can also be collapsed simply into process and outcome measures (see 
Appendix A, Table 1). For each indicator selected for use, a clear rationale and understandable definition will need 
to be agreed by key stakeholders and a standardised method of data collection described. A list of examples for 
indicators for use at national/international level is shown in Appendix A, Table 1. 
Data from national HIV surveillance systems should form an integral part of M&E of HIV testing programmes. 
Surveillance data should be used in the early stages of planning an HIV testing programme as well as for 
monitoring the impact of HIV testing programmes. Reports of new HIV diagnoses and prevalence surveys will help 
identify groups at highest risk of HIV (see Section 2.1). Analysis of these data over time provides insights into how 
large-scale initiatives are impacting on the epidemiology of HIV within the country as the number of new HIV 
diagnoses reflects patterns of both transmission and of HIV testing. These data are best presented by appropriate 
socio-demographic variables (e.g. age, sex or ethnicity) as well as most-at-risk groups (e.g. men who have sex 
with men, injecting drug users and migrants from high prevalence countries). 
Analyses of routine HIV data can be supplemented by second generation surveillance such as STI diagnoses and 
behavioural surveys. Regular behavioural surveys provide vital information to ascertain the success of programmes 
in increasing the uptake of HIV testing, especially in the most-at-risk groups. 
The proportion of new HIV cases that have been diagnosed late (i.e. after a point at which treatment should have 
been initiated – currently set at a CD4 count of less than 350 cells/mm3  or presenting with AIDS [13] can be used 
to assess the effectiveness of HIV testing programmes. If these programmes are successfully reaching those 
individuals with undiagnosed HIV infection, over time the number and proportion of individuals diagnosed late with 
HIV should fall. 
The proportion of HIV infected individuals who are unaware of their infection (the undiagnosed fraction), where 
available, is an important indicator which allows assessment of the true extent to which an HIV testing programme 
is reaching those who are already infected. As assessment of this proportion can be resource intensive, expensive 
and can raise ethical issues. Consideration should be given to conducting repeatable surveys among populations 
most at risk or restricting the surveillance to sentinel sites. 
3.2 Assessing HIV testing initiatives at the local level 
Reaching the population most at risk will require expanding testing in a number of clinical and community settings. 
It is critical that local HIV testing initiatives are subject to vigorous M&E to assess their success and inform future 
HIV testing policies and programmes. The success of local HIV testing initiatives can be assessed using the FACTS 
criteria. 
Feasibility. HIV testing programmes need to be implemented in feasible and appropriate settings, ensuring that 
adequate resources and staff are provided to implement the programme. Monitoring numbers and proportions of 
clients who are offered a test will provide information on how the initiative is working in practice and where there 
may be shortfalls in staff or resources. Audits of referral pathways are needed to ensure results are returned to 
patients and that those who test positive receive appropriate care and counselling in a timely manner. 
Acceptability. The offer of an HIV test must be acceptable to staff and the specific target group. It is important 
that the offer of a test is voluntary and confidential and that staff feel adequately trained to offer the HIV test with 
specialist backup if required. Surveys to assess the satisfaction of persons offered an HIV test and staff providing 
the service will be important in the early phase of implementation and may identify barriers to testing. Surveys 
should include a question on patient satisfaction and perceived stigma. Qualitative data from staff and patients 
derived from focus groups, interviews or diaries may also be used. These methods will provide an opportunity to 
collate opinions about the type of test used, the methods of providing results and referral pathways as well as 
attitudes towards the routine offer of the HIV test. The information can be used to modify local procedures for HIV 
testing, helping to maximise the offer and uptake of HIV tests. 
Effectiveness and Cost-effectiveness. A critical component of the success of an initiative is its ability to detect 
previously undiagnosed infections. The HIV positivity rate is a measure of the number of previously undiagnosed 
HIV infections detected among the population tested and is the key indicator for assessing effectiveness of the 
initiative. Trends in HIV positivity rates within a specific setting (e.g. emergency departments) will determine 
whether testing in this setting remains effective. It is also important to determine whether the resources and staff 
costs required to establish and sustain the programme are proportional to the results. The HIV positivity rate 
combined with the cost of the programme will assess its cost-effectiveness. Studies in the United States indicated 
that HIV testing is cost-effective in a setting where at least 1 in 1000 people tested are found to be infected with 
HIV (and were not previously diagnosed) [65,73,122]. A similar threshold for the European context is needed. 
Target populations are reached. Measuring the uptake of testing and HIV positivity rates in the populations 
most at risk (e.g. men who have sex with men and injecting drug users) will provide a measure of how effective 
the initiative is at reaching target populations and hence whether the initiative is accessible to that population 
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group. Likewise, positivity rates among groups most at risk will provide information on whether the initiative is 
serving the most appropriate population groups. 
Sustainability. HIV testing programmes need to be set up in a sustainable manner. Ongoing systematic review of 
M&E data by key stakeholders will help assess whether the programme remains fit for purpose, or needs to 
develop or evolve. For example, declining numbers of offers, or uptake, of HIV tests in the target population may 
indicate the need to promote testing to this group and reinvigorate interest among, and training of, staff involved 
in the programme. Setting targets and goals as part of an HIV strategy can provide incentives for local health 
services to achieve and maintain high rates of HIV testing. 
Examples of indicators for each of the FACTS criteria are provided in Appendix A, Table 2. 
3.3 Making it work 
It is important that the responsibilities for the maintenance of the M&E system are clearly demarcated and 
assigned at local and national levels. Those teams responsible for M&E systems need adequate resources and 
staffing and to have clear lines of communication between major stakeholders. 
Data systems will need to be regularly reviewed to ensure they are fit for purpose. It may be useful to assess their 
fitness using the SMARTER criteria: specific, measureable, attainable, relevant, timely, evaluated and re-evaluated. 
It is vital to the success of an HIV testing programme that patient confidentiality, and the perception of 
confidentiality, are preserved. This need must be balanced in M&E systems so that enough individual data are kept 
to allow meaningful interpretation but not to identify an individual. Thus, alongside assurances about the release of 
data and security of databases, codes may assist in creating confidential reporting systems [123]. 
A plan to disseminate results to key stakeholders in a regular and timely manner needs to be agreed. Where 
possible, local initiatives which form part of a larger national strategy should be rigorously evaluated and written 
up as reports and peer-reviewed articles to inform the ongoing development and refinement of the HIV testing 
programme. 
  
 
 
 
 
GUIDANCE REPORT HIV testing: increasing uptake and effectiveness in the European Union 
 
 
 
17 
 
 
 
References 
1. European Centre for Disease Prevention and Control. Implementing the Dublin Declaration on Partnership to fight 
HIV/AIDS in Europe and Central Asia: 2010 Progress Report. Stockholm: European Centre for Disease Prevention and 
Control. 2010.  
2. World Health Organization. Scaling up HIV testing and counseling in the WHO European Region - as an essential 
component of efforts to achieve universal access to HIV prevention, treatment, care and support. Policy framework. 
2010. Geneva: World Health Organization. 
3. Poljak M, Smit E, Ross J. 2008 European Guideline on HIV testing. Int J STD AIDS 2009;20(2):77-83. 
4. World Health Organization. Guidance on provider-initiated HIV testing and counselling in health facilities. WC 503.1. 
2007. Geneva: World Health Organization. 
5. World Health Organization/UNAIDS. Guidance on testing and counselling for HIV in settings attended by people who 
inject drugs. Improving access to treatment, care and prevention. 2009. Geneva: World Health Organization. 
6. European Centre for Disease Prevention and Control. HIV testing: Increasing uptake and effectiveness in the European 
Union. 2010. Evidence synthesis for Guidance on HIV testing. Stockholm: European Centre for Disease Prevention and 
Control. 
7. European Centre for Disease Prevention and Control/WHO Regional Office for Europe. HIV/AIDS surveillance in Europe 
2008. 2009. Stockholm: European Centre for Disease Prevention and Control. 
8. Hamers FF, Phillips AN. Diagnosed and undiagnosed HIV-infected populations in Europe. HIV Med. 2008;9(Suppl 2):6-
12. 
9. Adler A, Mounier-Jack S, Coker RJ. Late diagnosis of HIV in Europe: definitional and public health challenges. AIDS Care 
2009;21(3):284-93. 
10. Oppenheimer B, Arneborn M, Velicko I, Blaxhult A. Infected abroad--risk factor for late HIV diagnosis. Lakartidningen. 
2008 Jan 30-Feb 5;105(5):292-4. 
11. d’Arminio Monforte A, Cozzi-Lepri A, Fanti I, Maggiolo F, Castagna A, Prati F, et al; Icona Foundation Study Group. 
Proportion and trend over calendar time of patients with a low CD4 cell count or AIDS diagnosis at the time of their first 
contact with clinical care in Italy. 12th European AIDS Conference/European AIDS Clinical Society (EACS): Abstract 
LS2/2. 2009. 
12. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a 
public health approach. 2010 revision. Geneva: World Health Organization. 
13. Antinori A, Coenen T, Costagiola D, Dedes N, Ellefson M, Gatell J, et al; for the European Late Presenter Consensus 
working group. Late presentation of HIV infection: a consensus definition. HIV Med. 2010 Jun 17. 
14. Chadborn TR, Delpech VC, Sabin CA, Sinka K, Evans BG. The late diagnosis and consequent short-term mortality of 
HIV-infected heterosexuals (England and Wales, 2000-2004). AIDS. 2006 Nov 28;20(18):2371-9. 
15. Chadborn TR, Baster K, Delpech VC, Sabin CA, Sinka K, Rice BD, et al. No time to wait: how many HIV-infected 
homosexual men are diagnosed late and consequently die? (England and Wales, 1993-2002). AIDS. 2005 Mar 
25;19(5):513-20. 
16. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio Monforte A. Decline in the AIDS and death rates in the 
EuroSIDA study: an observational study. Lancet 2003;362(9377):22-9. 
17. Bhaskaran K, Hamouda O, Sannes M, Boufassa F, Johnson AM, Lambert PC, et al. Changes in the risk of death after 
HIV seroconversion compared with mortality in the general population. JAMA 2008;300(1):51-9. 
18. Smit C, Geskus RB, Uitenbroek D, Mulder D, van den Hoek A, Coutinho RA. Declining AIDS mortality in Amsterdam: 
contributions of declining HIV incidence and effective therapy. Epidemiology 2004;15(5):536-42. 
19. Couzigou C, Semaille C, Le Strat Y, Pinget R, Pillonel J, Lot F. Differential improvement in survival among patients with 
AIDS after the introduction of HAART. AIDS Care 2007;19(4):523-31. 
20. McNaghten AD, Hanson DL, Jones JL, Dworkin MS, Ward JW. Effects of antiretroviral therapy and opportunistic illness 
primary chemoprophylaxis on survival after AIDS diagnosis. Adult/Adolescent Spectrum of Disease Group. AIDS 
1999;13(13):1687-95. 
21. Chen RY, Accortt NA, Westfall AO, Mugavero MJ, Raper JL, Cloud GA, et al. Distribution of health care expenditures for 
HIV-infected patients. Clin Infect Dis. 2006 Apr 1;42(7):1003-10. Epub 2006 Feb 22. 
22. Krentz HB, Gill MJ. Cost of medical care for HIV-infected patients within a regional population from 1997 to 2006. HIV 
Med. 2008;9(9):721-30. 
23. Attia S, Egger M, Muller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and antiretroviral 
therapy: systematic review and meta-analysis. AIDS 2009;23(11):1397-404. 
 
 
 
 
HIV testing: increasing uptake and effectiveness in the European Union  GUIDANCE REPORT 
 
 
 
18 
 
 
 
24. Volmink J, Siegfried NL, van der ML, Brocklehurst P. Antiretrovirals for reducing the risk of mother-to-child transmission 
of HIV infection. Cochrane Database of Systematic Reviews. 2007(1):CD003510. Chichester, UK: John Wiley & Sons Ltd. 
25. World Health Organization. Antiretroviral drugs for treating pregnant women and preventing HIV infections in infants. 
Recommendations for a public health approach. 2010. Geneva: World Health Organization. 
26. Marks G, Crepaz N, Senterfitt JW, Janssen RS. Meta-analysis of high-risk sexual behavior in persons aware and 
unaware they are infected with HIV in the United States: implications for HIV prevention programs. J Acquir Immune 
Defic Syndr. 2005;39(4):446-53. 
27. Crepaz N, Marks G, Liau A, Mullins MM, Aupont LW, Marshall KJ, et al. Prevalence of unprotected anal intercourse 
among HIV-diagnosed MSM in the United States: a meta-analysis. AIDS 2009;23(13):1617-29. 
28. Fox J, White PJ, Macdonald N, Weber J, McClure M, Fidler S, et al. Reductions in HIV transmission risk behaviour 
following diagnosis of primary HIV infection: a cohort of high-risk men who have sex with men. HIV Med. 
2009;10(7):432-8. 
29. Erwin J, Morgan M, Britten N, Gray K, Peters B. Pathways to HIV testing and care by black African and white patients in 
London. Sex.Transm.Infect. 2002;78(1):37-9. 
30. Burns FM, Imrie JY, Nazroo J, Johnson AM, Fenton KA. Why the(y) wait? Key informant understandings of factors 
contributing to late presentation and poor utilization of HIV health and social care services by African migrants in Britain. 
AIDS Care 2007;19(1):102-8. 
31. Prost A, Elford J, Imrie J, Petticrew M, Hart GJ. Social, behavioural, and intervention research among people of Sub-
Saharan African origin living with HIV in the UK and Europe: literature review and recommendations for intervention. 
AIDS Behav. 2008;12(2):170-94. 
32. Nnoaham KE, Pool R, Bothamley G, Grant AD. Perceptions and experiences of tuberculosis among African patients 
attending a tuberculosis clinic in London. Int J Tuberc Lung Dis. 2006;10(9):1013-7. 
33. Manirankunda L, Loos J, Alou TA, Colebunders R, Nostlinger C. "It's better not to know": perceived barriers to HIV 
voluntary counseling and testing among sub-Saharan African migrants in Belgium. AIDS Educ Prev. 2009;21(6):582-93. 
34. de Wit JB, Adam PC. To test or not to test: psychosocial barriers to HIV testing in high-income countries. HIV Med. 
2008;9(Suppl 2):20-2. 
35. Nicoll A, Hughes G, Donnelly M, Livingstone S, De Angelis D, Fenton K, et al. Assessing the impact of national anti-HIV 
sexual health campaigns: trends in the transmission of HIV and other sexually transmitted infections in England. Sex 
Transm Infect. 2001;77(4):242-7. 
36. Vidanapathirana J, Abramson MJ, Forbes A, Fairley C. Mass media interventions for promoting HIV testing. Cochrane 
Database of Systematic Reviews: 2005 (3). Chichester, UK: John Wiley & Sons Ltd. 
37. Deblonde J, De Koker P, Hamers FF, Fontaine J, Luchters S, Temmerman M. Barriers to HIV testing in Europe: a 
systematic review. Eur J Public Health. 2010;20(4):422-32. 
38. Gańczak M, Barss P. Fear of HIV infection and impact of training on the attitudes of surgical and emergency nurses 
toward inpatient HIV testing. Infect Control Hosp Epidemiol. 2007;28(2):230-3. 
39. Lohrmann C, Valimaki M, Suominen T, Muinonen U, Dassen T, Peate I. German nursing students' knowledge of and 
attitudes to HIV and AIDS: two decades after the first AIDS cases. J Adv Nurs. 2000;31(3):696-703. 
40. Joint United Nations Programme on HIV/AIDS and United Nations Development Programme. International Consultation 
on the Criminalization of HIV Transmission. 2007. Geneva: Joint United Nations Programme on HIV/AIDS. 
41. Office of the United Nations High Commissioner for Human Rights and the Joint United Nations Programme on 
HIV/AIDS. International Guidelines on HIV/AIDS and Human Rights. 2006 Consolidated Version. Geneva: UNHCR. 
42. Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and practice: the contribution of other 
sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect. 1999 Feb;75(1):3-17. 
43. Cohen MS. Sexually transmitted diseases enhance HIV transmission: no longer a hypothesis. Lancet. 1998;351(Suppl 
3):5-7. 
44. Deblonde J, Claeys P, Temmerman M. Antenatal HIV screening in Europe: a review of policies. Eur J Public Health 
2007;17(5):414-8 
45. Gazzard B, Clumeck N, d'Arminio MA, Lundgren JD. Indicator disease-guided testing for HIV--the next step for Europe? 
HIV Med. 2008;9(Suppl 2):34-40. 
46. British HIV Association, British Association for Sexual Health and HIV, and British Infection Society. UK National 
Guidelines for HIV Testing 2008. 2008. London: British HIV Association. 
47. United Nations Office on Drugs and Crime, World Health Organization & UNAIDS. Policy brief. HIV testing and 
counselling in prisons and other closed settings. October 2009. Vienna: United Nations Office on Drugs and Crime.  
48. UNAIDS/ World Health Organization Working Group on Global HIV/AIDS and STI Surveillance (2005). The pre-
surveillance assessment: guidelines for planning serosurveillance of HIV, prevalence of sexually transmitted infections 
 
 
 
 
GUIDANCE REPORT HIV testing: increasing uptake and effectiveness in the European Union 
 
 
 
19 
 
 
 
and the behavioural components of second generation surveillance of HIV. Geneva: World Health 
Organization/UNAIDS/Family Health International. 
49. European Centre for Disease Prevention and Control. Mapping of HIV/STI surveillance systems in Europe. ECDC 
Technical Report. 2009. Stockholm: European Centre for Disease Prevention and Control. 
50. Suligoi B, Raimondo M, Fanales-Belasio E, Buttò S. The epidemic of HIV infection and AIDS, promotion of testing, and 
innovative strategies. Ann Ist Super Sanita. 2010;46(1):15-23. 
51. Likatavicius G, Hamers FF, Downs AM, Alix J, Nardone A. Trends in HIV prevalence in blood donations in Europe, 1990-
2004. AIDS 2007;21(8):1011-8. 
52. Girardi E, Sabin CA, Monforte AD. Late diagnosis of HIV infection: epidemiological features, consequences and 
strategies to encourage earlier testing. J Acquir Immune Defic Syndr. 2007 Sep;46 (Suppl 1):S3-8. 
53. Downing M, Knight K, Reiss TH, Vernon K, Mulia N, Ferreboeuf M, et al. Drug users talk about HIV testing: motivating 
and deterring factors. AIDS Care. 2001 Oct;13(5):561-77. 
54. Obermeyer CM, Osborn M. The utilization of testing and counseling for HIV: a review of the social and behavioral 
evidence. Am J Public Health. 2007 Oct;97(10):1762-74. Epub 2007 Aug 29. 
55. Spielberg F, Branson BM, Goldbaum GM, Lockhart D, Kurth A, Celum CL, et al. Overcoming barriers to HIV testing: 
preferences for new strategies among clients of a needle exchange, a sexually transmitted disease clinic, and sex 
venues for men who have sex with men. J Acquir Immune Defic Syndr. 2003;32(3):318-27. 
56. Chen Z, Branson B, Ballenger A, Peterman TA. Risk assessment to improve targeting of HIV counseling and testing 
services for STD clinic patients. Sex Transm Dis. 1998;25(10):539-43. 
57. Manavi K, Clutterbuck D, Mackay R, McMillan A, Scott G. A rapid method for identifying high-risk patients consenting for 
HIV testing: introducing The Edinburgh Risk Assessment Table for HIV testing. Int J STD AIDS 2006;17(4):234-6. 
58. Degenhardt L, Hall W, Lynskey M, Warner-Smith M. Illicit Drug Use. Comparative quantification of health risks: global 
and regional burden of disease attributable to selected major risk factors. 2004. Geneva: World Health Organization; 
1109-76. 
59. Mathers BM, Degenhardt L, Ali H, Wiessing L, Hickman M, Mattick RP, et al. HIV prevention, treatment, and care 
services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet 
2010;375(9719):1014-28. 
60. Samson L, King S. Evidence-based guidelines for universal counselling and offering of HIV testing in pregnancy in 
Canada. CMAJ. 1998;158(11):1449-57. 
61. Chou R, Smits AK, Huffman LH, Fu R, Korthuis PT. Prenatal screening for HIV: A review of the evidence for the U.S. 
Preventive Services Task Force. Ann Intern Med. 2005;143(1):38-54. 
62. Townsend CL, Cliffe S, Tookey PA. Uptake of antenatal HIV testing in the United Kingdom: 2000-2003. J Public Health 
(Oxf) 2006;28(3):248-52. 
63. Raba G, Skret-Magierlo J, Skret A. Knowledge about HIV infection and acceptability of HIV testing among women 
delivered in Podkarpackie Province, Poland. Int J.Gynaecol Obstet. 2010;108(2):108-10. 
64. Sturtevant D, Preiksaitis J, Singh A, Houston S, Gill J, Predy G, et al. The feasibility of using an 'opt-out' approach to 
achieve universal HIV testing of tuberculosis patients in Alberta. Can J Public Health 2009;100(2):116-20. 
65. Sanders GD, Bayoumi AM, Sundaram V, Bilir SP, Neukermans CP, Rydzak CE, et al. Cost-effectiveness of screening for 
HIV in the era of highly active antiretroviral therapy. N Engl J Med. 2005;352(6):570-85. 
66. Fakoya I, Reynolds R, Caswell G, Shiripinda I. Barriers to HIV testing for migrant black Africans in Western Europe. HIV 
Med. 2008;9(Suppl 2):23-5. 
67. Blystad H, Wiessing L. Guidance on Provider-initiated Voluntary Medical Examination, Testing and Counselling for 
Infectious Diseases in Injecting Drug Users. Pre-final unedited version 5.5. EMCDDA. Lisbon: 2009. 
68. Leaity S, Sherr L, Wells H, Evans A, Miller R, Johnson M, et al. Repeat HIV testing: high-risk behaviour or risk reduction 
strategy? AIDS 2000;14(5):547-52. 
69. Fernyak SE, Page-Shafer K, Kellogg TA, McFarland W, Katz MH. Risk behaviors and HIV incidence among repeat testers 
at publicly funded HIV testing sites in San Francisco. J Acquir Immune Defic Syndr. 2002;31(1):63-70. 
70. Hightow LB, Miller WC, Leone PA, Wohl DA, Smurzynski M, Kaplan AH. Predictors of repeat testing and HIV 
seroconversion in a sexually transmitted disease clinic population. Sex Transm Dis. 2004;31(8):455-9. 
71. MacKellar DA, Valleroy LA, Secura GM, Bartholow BN, McFarland W, Shehan D, et al. Repeat HIV testing, risk behaviors, 
and HIV seroconversion among young men who have sex with men: a call to monitor and improve the practice of 
prevention. J Acquir Immune Defic Syndr. 2002;29(1):76-85. 
72. Guy R, Goller JL, Spelman T, El Hayek C, Gold J, Lim M, et al. Does the frequency of HIV and STI testing among MSM 
in primary care adhere with Australian guidelines? Sex Transm Infect. 2010. May 10. [Epub ahead of print] 
 
 
 
 
HIV testing: increasing uptake and effectiveness in the European Union  GUIDANCE REPORT 
 
 
 
20 
 
 
 
73. Paltiel AD, Weinstein MC, Kimmel AD, Seage GR, III, Losina E, Zhang H, et al. Expanded screening for HIV in the 
United States--an analysis of cost-effectiveness. N Engl J Med. 2005;352(6):586-95. 
74. Haute Autorité de Santé. Dépistage de l'infection par le VIH en France - Stratégies et dispositif de dépistage. 2009. 
Saint-Denis La Plaine, France. 
75. Noar SM, Palmgreen P, Chabot M, Dobransky N, Zimmerman RS. A 10-year systematic review of HIV/AIDS mass 
communication campaigns: Have we made progress? J Health Commun. 2009;14(1):15-42. 
76. Guy RJ, Prybylski D, Fairley CK, Hellard ME, Kaldor JM. Can data from HIV voluntary counselling and testing be used to 
assess the impact of public health interventions? A literature review. Int J STD AIDS 2009;20(6):378-83. 
77. Burns FM, Johnson AM, Nazroo J, Ainsworth J, Anderson J, Fakoya A, et al. Missed opportunities for earlier HIV 
diagnosis within primary and secondary healthcare settings in the UK. AIDS 2008;22(1):115-22. 
78. Sasse A, Vincent A, Galand M, Ryckmans P, Liesnard C. High HIV prevalence among patients choosing anonymous and 
free testing in Belgium, 1990-2002. Int J STD AIDS. 2006 Dec;17(12):817-20. 
79. McDonald EA, Currie MJ, Bowden FJ. Delayed diagnosis of HIV: missed opportunities and triggers for testing in the 
Australian Capital Territory. Sex Health 2006;3(4):291-5. 
80. Tipnis SR, Fox EF. Uptake of HIV testing in a busy South London GU medicine clinic--will we reach targets set in the 
National Strategy and are we testing those at risk? Int J STD AIDS 2006;17(7):484-5. 
81. Cohan D, Gomez E, Charlebois E. Patient Perspectives and Testing Uptake with Abbreviated versus Standard Pretest 
HIV Counseling in the Prenatal Setting: A Randomized-Controlled, Non-inferiority Trial. 15th Conference on Retroviruses 
and Opportunistic Infections (Boston, MA). Abstract 535a; 2008. 
82. Burke RC, Sepkowitz KA, Bernstein KT, Karpati AM, Myers JE, Tsoi BW, et al. Why don't physicians test for HIV? A 
review of the US literature. AIDS 2007;21(12):1617-24. 
83. Partridge DG, Collini P, McKendrick MW. HIV testing: the boundaries. A survey of HIV testing practices and barriers to 
more widespread testing in a British teaching hospital. Int J STD AIDS 2009;20(6):427-8. 
84. Cohan D, Gomez E, Dowling T, Zetola N, Kaplan B, Klausner JD. HIV testing attitudes and practices among clinicians in 
the era of updated Centers for Disease Control and Prevention recommendations. J Acquir Immune Defic Syndr. 
2009;50(1):114-6. 
85. Hansen L, Barnett J, Wong T, Spencer D, Rekart M. STD and HIV counseling practices of British Columbia primary care 
physicians. AIDS Patient Care STDS. 2005;19(1):40-8. 
86. Cohan D, Gomez E, Greenberg M, Washington S, Charlebois ED. Patient perspectives with abbreviated versus standard 
pre-test HIV counseling in the prenatal setting: a randomized-controlled, non-inferiority trial. PLoS One. 
2009;4(4):e5166. 
87. Ehrenkranz PD, Pagan JA, Begier EM, Linas BP, Madison K, Armstrong K. Written informed-consent statutes and HIV 
testing. Am J Prev Med. 2009;37(1):57-63. 
88. Wing C. Effects of written informed consent requirements on HIV testing rates: evidence from a natural experiment. 
Am J Public Health 2009;99(6):1087-92. 
89. World Health Organization. Guidelines for Assuring the Accuracy and Reliability of HIV Rapid Testing: Applying a Quality 
System Approach. 2005. Geneva: World Health Organization. 
90. Branson BH, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and 
pregnant women in health-care settings. Mol Morb Wkly Rep 2006;55:1–17. 
91. Parry JV, Mortimer PP, Perry KR, Pillay D, Zuckerman M. Towards error-free HIV diagnosis: guidelines on laboratory 
practice. Commun Dis Public Health 2003;6:334–50. 
92. Wurcel A, Zaman T, Zhen S, Stone D. Acceptance of HIV antibody testing among inpatients and outpatients at a public 
health hospital: a study of rapid versus standard testing. AIDS Patient.Care STDS. 2005;19(8):499-505. 
93. Haukoos JS, Hopkins E, Byyny RL. Patient acceptance of rapid HIV testing practices in an urban emergency department: 
assessment of the 2006 CDC recommendations for HIV screening in health care settings. Ann Emerg Med. 
2008;51(3):303-9, 309. 
94. Silva A, Glick NR, Lyss SB, Hutchinson AB, Gift TL, Pealer LN, et al. Implementing an HIV and sexually transmitted 
disease screening program in an emergency department. Ann Emerg Med. 2007;49(5):564-72. 
95. Antonio-Gaddy M, Richardson-Moore A, Burstein GR, Newman DR, Branson BM, Birkhead GS. Rapid HIV antibody 
testing in the New York State Anonymous HIV Counseling and Testing Program: experience from the field. J Acquir 
Immune Defic Syndr. 2006;43(4):446-50. 
96. Mugezi R, Barrat A, Wilkinson A, Waters A, McOwan A, Sullivan A. KNOW4SURE - a community-based rapid point of 
care test (POCT) clinic. HIV Med. 2005;6(Suppl 1):Abstract P137. 
 
 
 
 
GUIDANCE REPORT HIV testing: increasing uptake and effectiveness in the European Union 
 
 
 
21 
 
 
 
97. Weatherburn P, Clarke M, Pye K, Sharkey K, Russell T, Smith C, et al. HIV testing for African people and MSM: 
comparing needs access and effectiveness in clinic and community settings in a UK city. HIV Med. 2006;7(Suppl 
1):Abstract P82. 
98. Smith LV, Rudy ET, Javanbakht M, Uniyal A, Sy LS, Horton T, et al. Client satisfaction with rapid HIV testing: 
comparison between an urban sexually transmitted disease clinic and a community-based testing center. AIDS Patient 
Care STDS. 2006;20(10):693-700. 
99. Van Loon S, Koevoets W. Rapid HIV testing in a one-hour procedure motivates MSM in the Netherlands to take the test. 
The XV International AIDS Conference. Bangkok, Thailand: Abstract WePeC6099; 2004. 
100. Huebner DM, Binson D, Dilworth SE, Neilands TB, Grinstead O, Woods WJ. Rapid vs. standard HIV testing in 
bathhouses: what is gained and lost? AIDS Behav. 2010;14(3):688-96. 
101. Anaya HD, Hoang T, Golden JF, Goetz MB, Gifford A, Bowman C, et al. Improving HIV screening and receipt of results 
by nurse-initiated streamlined counseling and rapid testing. J Gen Intern Med. 2008;23(6):800-7. 
102. Hutchinson AB, Branson BM, Kim A, Farnham PG. A meta-analysis of the effectiveness of alternative HIV counseling 
and testing methods to increase knowledge of HIV status. AIDS 2006;20(12):1597-604. 
103. Stokes SH, McMaster P, Ismail KM. Acceptability of perinatal rapid point-of-care HIV testing in an area of low HIV 
prevalence in the UK. Arch Dis Child 2007;92(6):505-8. 
104. Metcalf CA, Douglas JM, Jr., Malotte CK, Cross H, Dillon BA, Paul SM, et al. Relative efficacy of prevention counseling 
with rapid and standard HIV testing: a randomized, controlled trial (RESPECT-2). Sex Transm Dis. 2005;32(2):130-8. 
105. Kendrick SR, Kroc KA, Withum D, Rydman RJ, Branson BM, Weinstein RA. Outcomes of offering rapid point-of-care HIV 
testing in a sexually transmitted disease clinic. J Acquir Immune Defic Syndr. 2005;38(2):142-6. 
106. Reynolds GL, Fisher DG, Napper LE, Marsh KA, Willey C, Brooks R. Results from a multiple morbidities testing program 
offering rapid HIV testing bundled with hepatitis and sexually transmitted infection testing. Public Health Rep. 2008;123 
(Suppl 3):63-9. 
107. Spielberg F, Branson BM, Goldbaum GM, Lockhart D, Kurth A, Rossini A, et al. Choosing HIV Counseling and Testing 
Strategies for Outreach Settings: A Randomized Trial. J Acquir Immune Defic Syndr. 2005;38(3):348-55. 
108. Pugatch DL, Levesque BG, Lally MA, Reinert SE, Filippone WJ, Combs CM, et al. HIV testing among young adults and 
older adolescents in the setting of acute substance abuse treatment. J Acquir Immune Defic Syndr. 2001;27(2):135-42. 
109. Bowles KE, Clark HA, Tai E, Sullivan PS, Song B, Tsang J, et al. Implementing rapid HIV testing in outreach and 
community settings: results from an advancing HIV prevention demonstration project conducted in seven U.S. cities. 
Public Health Rep. 2008;123 (Suppl 3):78-85. 
110. Wright S, Kell P, Tobin R. How do clients access their HIV test results from genitourinary medicine services in the UK? A 
time for change! Int J STD AIDS 2004;15(9):584-6. 
111. Hightow LB, Miller WC, Leone PA, Wohl D, Smurzynski M, Kaplan AH. Failure to return for HIV posttest counseling in an 
STD clinic population. AIDS Educ Prev. 2003;15(3):282-90. 
112. Molitor F, Bell RA, Truax SR, Ruiz JD, Sun RK. Predictors of failure to return for HIV test result and counseling by test 
site type. AIDS Educ Prev. 1999;11(1):1-13. 
113. Sullivan PS, Lansky A, Drake A. Failure to return for HIV test results among persons at high risk for HIV infection: 
results from a multistate interview project. J Acquir Immune Defic Syndr. 2004;35(5):511-8. 
114. British HIV Association, Royal College of Physicians, British Association for Sexual Health and HIV, and British Infection 
Society. Standards for HIV clinical care. 2007. London: British HIV Association. 
115. Weinhardt LS, Carey MP, Johnson BT, Bickham NL. Effects of HIV counseling and testing on sexual risk behavior: a 
meta-analytic review of published research, 1985-1997. Am J Public Health 1999;89(9):1397-405. 
116. Rotheram-Borus MJ, Swendeman D, Comulada WS, Weiss RE, Lee M, Lightfoot M. Prevention for substance-using HIV-
positive young people: telephone and in-person delivery. J Acquir Immune Defic Syndr. 2004;37 Suppl 2:S68-S77. 
117. Margolin A, Avants SK, Warburton LA, Hawkins KA, Shi J. A randomized clinical trial of a manual-guided risk reduction 
intervention for HIV-positive injection drug users. Health Psychol. 2003;22(2):223-8. 
118. UNAIDS. Monitoring the Declaration of Commitment on HIV/AIDS. Guidelines on the construction of core indicators. 
2009. 
http://www.unaids.org/en/KnowledgeCentre/Resources/FeatureStories/archive/2009/20090331_UNGASS2010.asp 
[Accessed 01/10/2010]. 
119. World Health Organization. A Handbook for Improving HIV Testing and Counselling Services. In press. By personal 
communication. 
120. World Health Organization. Guide for Monitoring and Evaluating national HIV testing and counselling (HTC) 
programmes. In press. By personal communication. 
 
 
 
 
HIV testing: increasing uptake and effectiveness in the European Union  GUIDANCE REPORT 
 
 
 
22 
 
 
 
121. European Centre for Disease Prevention and Control. Mapping of HIV/STI behavioural surveillance in Europe. 
Stockholm: European Centre for Disease Prevention and Control. 2009. 
122. Walensky RP, Weinstein MC, Kimmel AD, Seage GR 3rd, Losina E, Sax PE, et al. Routine human immunodeficiency virus 
testing: an economic evaluation of current guidelines. Am J Med. 2005 Mar;118(3):292-300. 
123. Mortimer JY, Salathiel JA. ‘Soundex' codes of surnames provide confidentiality and accuracy in a national HIV database. 
Commun Dis Rep CDR Rev. 1995;5(12):R183-6. 
  
 
 
 
 
GUIDANCE REPORT HIV testing: increasing uptake and effectiveness in the European Union 
 
 
 
23 
 
 
 
Appendix A 
Table 1: Monitoring and evaluation at the national/international level 
 Examples of indicators References 
Process 
indicators 
Existence of national testing policies and guidelines that are 
consistent with international standards (WHO/AIDS) 
UNGASS (as part of 
National Composite 
Policy Index), WHO 
M&E guide 
% men and women who had an HIV test in the last 12 
months and know the results 
UNGASS, WHO M&E 
guide 
% of most-at-risk populations (MSM, IDU, migrants) who had 
an HIV test in the last 12 months and know their results 
UNGASS, WHO M&E 
guide 
% of pregnant women who have been tested for HIV in the 
last 12 months and know their results WHO M&E guide 
% of TB patients who have been tested for HIV in the last 12 
months and know their results WHO M&E guide 
% of STI patients who have been tested for HIV in the last 
12 months and know their results ECDC 
Numbers and proportions of persons offered testing stratified 
by setting (particularly, anonymous testing sites and primary 
care sites) 
 
Outcome 
indicators 
Total number of new diagnoses stratified by most-at-risk 
populations including unknowns Dublin Declaration 
Number and % of new diagnoses which are diagnosed late 
with CD4 <200 (overall and by most-at-risk population) 
Number and % of new diagnoses which are diagnosed late 
with CD4 <350 (overall and by most-at-risk population) 
Number and % of new diagnoses which are diagnosed late 
with AIDS at presentation (overall and by most-at-risk 
population) 
Dublin Declaration 
% new diagnoses who are recently infected (RITA or other 
seroconversion algorithms)  
% of newly diagnosed individuals who are successfully 
transferred to care within three months (overall and by most-
at-risk populations) 
WHO M&E guide 
Total number and proportion of undiagnosed infections  
Number and proportion in most-at-risk groups of 
undiagnosed infections  
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Table 2: Monitoring and evaluation in specific settings 
Examples of indicators to assess local HIV testing initiatives using the FACTS criteria  
Criteria for project success Examples of indicators 
Feasibility 
Number and % of persons offered HIV testing 
% newly diagnosed individuals who are successfully 
transferred to care within three months 
Acceptability 
Number and % uptake of an HIV test (overall and 
among populations most at risk) 
% of patients agreeing that the offer of an HIV test in 
this setting is acceptable 
% of patients willing to disclose risk behaviour 
% of patients satisfied with the patient information 
provided 
% of staff reporting barriers to offer an HIV test in this 
setting 
% of staff reporting specific training needs 
Effectiveness and cost effectiveness 
Positivity rate (overall and among populations most at 
risk) 
Staff costs associated with intervention 
Resource costs associated with intervention 
Outcome of cost-effectiveness model 
Target populations reached 
% of most-at-risk populations who had an HIV test in 
the last 12 months and know their results 
Positivity rate among most-at-risk populations tested 
in the setting 
Sustainability 
Number and % uptake of an HIV test (overall and 
among populations most at risk) 
Staff costs associated with intervention 
Resource costs associated with intervention 
 
  
 
 
 
 
GUIDANCE REPORT HIV testing: increasing uptake and effectiveness in the European Union 
 
 
 
25 
 
 
 
Appendix B 
Clinical indicator conditions for HIV infection 
Table 3: AIDS-defining illness and other illnesses strongly associated with immunodeficiency in HIV-
infected populations 
Candidiasis of the bronchi, trachea or lungs Kaposi’s sarcoma 
Candidiasis (oesophageal) 
Lymphoma, Burkitt’s 
Lymphoma (immunoblastic) 
Cervical cancer (invasive) Lymphoma (primary) of the brain 
Coccidioidomycosis (disseminated or extrapulmonary) Mycobacterium avium complex or Mycobacterium kansasii (disseminated or extrapulmonary) 
Cryptococcosis (extrapulmonary) Mycobacterium tuberculosis, any site (extrapulmonary or pulmonary) 
Cryptosporidiosis, chronic intestinal (>1 month’s duration) Mycobacterium, other species or unidentified species (disseminated or extrapulmonary) 
Cytomegalovirus disease (other than liver, spleen or 
nodes) Pneumocystis jirovecii pneumonia 
Cytomegalovirus retinitis (with loss of vision) Pneumonia (recurrent) 
Encephalopathy (HIV-related) Progressive multifocal leukoencephalopathy 
Herpes simplex: chronic ulcer(s) (>1 month’s duration); or 
bronchitis, pneumonitis or oesophagitis Salmonella septicaemia (recurrent) 
Histoplasmosis (disseminated or extrapulmonary) Toxoplasmosis of the brain 
Isosporiasis (chronic intestinal (>1 month’s duration)) Wasting syndrome due to HIV 
 
Adapted from: Gazzard B, Clumeck N, d'Arminio Monforte A, Lundgren JD. Indicator disease-guided testing for HIV—the next 
step for Europe? HIV Med. 2008 Jul;9 Suppl 2:34-40. Review. 
References 
Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case 
definition for AIDS among adolescents and adults. Morbid Mortal Weekly Rep 1992;41:1–19. 
Emery S, Abrams DI, Cooper DA, Darbyshire JH, Lane HC, Lundgren JD, et al. The evaluation of subcutaneous proleukin 
(interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRIT. Control Clin Trials 2002 
Apr;23(2):198-220. 
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HIV prevalence in patients with clinical indicator conditions 
in Europe 
Table 4: Prevalence of HIV in patients presenting with various indicator diseases (European studies) 
Disease HIV prevalence References 
1 Candidiasis 6–23% 
Tortorano AM, Biraghi E, Astolfi A, Ossi C, Tejada M, Farina C, et al; FIMUA 
Candidemia Study Group. European Confederation of Medical Mycology 
(ECMM) prospective survey of candidaemia: report from one Italian region. 
J Hosp Infect 2002; 51: 297–304. 
Tortorano AM, Rigoni AL, Biraghi E, Prigitano A, Viviani MA; FIMUA-ECMM 
Candidaemia Study Group. The European Confederation of Medical 
Mycology (ECMM) survey of candidaemia in Italy: antifungal susceptibility 
patterns of 261 non-albicans Candida isolates from blood. J Antimicrob 
Chemother 2003; 52: 679–682. 
2 Herpes zoster Unknown  
3 Fungal infections of the skin   
 Cryptococcosis 77% 
Dromer F, Mathoulin-Pélissier S, Launay O, Lortholary O; French 
Cryptococcosis Study Group. Determinants of disease presentation and 
outcome during cryptococcosis: the CryptoA/D study. PLoS Med 2007; 4: 
e21. 
4 Oral manifestations of HIV disease Unknown  
5 Sexually transmitted infections   
 Hepatitis B Unknown  
 Hepatitis C 8–59% 
Bini EJ, Currie SL, Shen H, Bräu N, Schmidt W, Anand BS, et al; VA HCV-001 
Study Group National multicenter study of HIV testing and HIV seropositivity 
in patients with chronic hepatitis C virus infection. J Clin Gastroenterol 2006; 
40:732–739. 
Cacoub P, Renou C, Rosenthal E, Cohen P, Loury I, Loustaud-Ratti V, et al. 
Extrahepatic manifestations associated with hepatitis C virus infection. A 
prospective multicenter study of 321 patients. The GERMIVIC. Groupe 
d’Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le 
Virus de l’Hepatite C. Medicine (Baltimore) 2000; 79: 47–56. 
Posthouwer D, Makris M, Yee TT, Fischer K, van Veen JJ, Griffioen A, et al. 
Progression to end-stage liver disease in patients with inherited bleeding 
disorders and hepatitis C: an international, multicenter cohort study. Blood 
2007; 109: 3667–3671. 
Raguin G, Rosenthal E, Cacoub P, Veyssier P, Piette JC, Micoud M. Hepatitis 
C in France: a national survey in the Departments of Internal Medicine and 
Infectious Diseases. The GERMIVIC (Joint Study Group on Hepatitis C virus 
of the French National Society of Internal Medicine and the French Society 
of Infectious Diseases). Eur J Epidemiol 1998; 14: 545–548. 
 Lymphogranuloma venereum 74% 
Jebbari H, Alexander S, Ward H, Evans B, Solomou M, Thornton A, et al; UK 
LGV Incident Group. Update on lymphogranuloma venereum in the United 
Kingdom. Sex Transm Infect 2007; 83: 324–326. 
6 Pregnancy   
 France 0.34% 
Hudson C, Bergenstrom A, Bell E, McCann E, Sherr L. The dilemma of 
antenatal HIV testing: what goes on in the European Community? J Roy Soc 
Med 1999; 92:273–276. 
 Greece 0.1% 
Hudson C, Bergenstrom A, Bell E, McCann E, Sherr L. The dilemma of 
antenatal HIV testing: what goes on in the European Community? J Roy Soc 
Med 1999; 92:273–276. 
 Italy 0.1–0.3% 
Hudson C, Bergenstrom A, Bell E, McCann E, Sherr L. The dilemma of 
antenatal HIV testing: what goes on in the European Community? J Roy Soc 
Med 1999; 92:273–276. 
 Netherlands 0.3% 
Cocu M, Thorne C, Mătuşa R, Tica V, Florea C, Asandi S, Giaquinto C. 
Mother-to-child transmission of HIV infection in Romania: results from an 
education and prevention programme. AIDS Care 2005; 17:76–84. 
 Romania 0.2% 
Simpson W, Johnstone F, Goldberg D, Gormley S, Hart G. Antenatal HIV 
testing: assessment of a routine voluntary approach. Br Med J 1999; 318: 
1660–1661. 
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Disease HIV prevalence References 
 Scotland 0.2% 
Hudson C, Bergenstrom A, Bell E, McCann E, Sherr L. The dilemma of 
antenatal HIV testing: what goes on in the European Community? J Roy Soc 
Med 1999; 92:273–276. 
 UK 0.01–0.26% 
Hudson C, Bergenstrom A, Bell E, McCann E, Sherr L. The dilemma of 
antenatal HIV testing: what goes on in the European Community? J Roy Soc 
Med 1999; 92:273–276. 
7 Respiratory infections   
 Tuberculosis 10–25% 
Melzer M, Warley A, Milburn H, O'Sullivan D, Barker RD, Hutchinson D, et al. 
Tuberculosis and HIV seroprevalence in Lambeth, Southwark and Lewisham, 
an area of South London. Respir Med 2003; 97: 167–172. 
Scotto G, Saracino A, El-Hamed I, Iannece MD, Geraci S, Palumbo E, et al. 
Epidemiology of tuberculosis in immigrant patients hospitalised in Infectious 
Diseases Units in Italy: multicentric study. Infez Med 2004; 12:245–251 
[Article in Italian]. 
Tattevin P, Casalino E, Fleury L, Egmann G, Ruel M, Bouvet E. The validity 
of medical history, classic symptoms, and chest radiographs in predicting 
pulmonary tuberculosis: derivation of a pulmonary tuberculosis prediction 
model. Chest 1999;115: 1248–1253. 
 Community-acquired pneumonia 19–24% 
Goss CH, Rubenfeld GD, Park DR, Sherbin VL, Goodman MS, Root RK. Cost 
and incidence of social comorbidities in low-risk patients with 
communityacquired pneumonia admitted to a public hospital. Chest 
2003;124: 2148–2155. 
Vallès X, Marcos A, Pinart M, Piñer R, Marco F, Mensa JM, et al. Hospitalized 
community-acquired pneumonia due to Streptococcus pneumoniae: has 
resistance to antibiotics decreased? Chest 2006; 130:800–806. 
8 Neurological disease   
 Meningitis (cryptococcosis) 68–94% 
Dromer F, Mathoulin-Pélissier S, Launay O, Lortholary O; French 
Cryptococcosis Study Group. Determinants of disease presentation and 
outcome during cryptococcosis: the CryptoA/D study. PLoS Med 2007; 4: 
e21. 
Tintelnot K, Lemmer K, Losert H, Schär G, Polak A. Follow-up of 
epidemiological data of cryptococcosis in Austria, Germany and Switzerland 
with special focus on the characterization of clinical isolates. Mycoses 2004; 
47: 455–464. 
ECMM. European Confederation of Medical Mycology (ECMM) prospective 
survey of cryptococcosis: report from Italy. Med Mycol 2002; 40: 507–517. 
 Perinatal listeriosis 3% 
Nolla-Salas J, Bosch J, Gasser I, Vinas L, de Simon M, Almela M, et al. 
Perinatal listeriosis: a population-based multicenter study in Barcelona, 
Spain (1990–1996). Am J Perinatol 1998; 15: 461–467. 
9 Gastroenterology   
 Nosocomial diarrhoea 10–12% 
Bauer TM, Lalvani A, Fehrenbach J, Steffen I, Aponte JJ, Segovia R, et al. 
Derivation and validation of guidelines for stool cultures for 
enteropathogenic bacteria other than Clostridium difficile in hospitalized 
adults. J Am Med Assoc 2001; 285: 313–319. 
García-Rodríguez JA, Martín Sánchez AM, Canut Blasco A, García Luis EJ, 
Luna Rodrigo G. Incidence of Cryptosporidium sp. in patients treated in a 
general hospital. Technics for the identification of oocysts in feces. Med Clin 
(Barcelona) 1989; 93: 164–168 [Article in Spanish]. 
10  Constitutional symptoms   
 Unexplained fever 3% Doherty JF, Grant AD, Bryceson AD. Fever as the presenting complaint of 
travellers returning from the tropics. QJM 1995;88: 277–281. 
11 Mononucleosis 7% 
Bottieau E, Clerinx J, Van den Enden E, Van Esbroeck M, Colebunders R, 
Van Gompel A, et al. Infectious mononucleosis-like syndromes in febrile 
travelers returning from the tropics. J Travel Med 2006; 13: 191–197. 
12 Laboratory indicators Unknown  
13 Tumours   
 Kaposi’s sarcoma 45.4%* 
Larocca L, Leto D, Celesta BM, Maccarone S, Mazza C, Cacopardo B, et al. 
Prevalence of antibodies to HHV-8 in the general population and in 
individuals at risk for sexually transmitted and blood-borne infections in 
Catania, Eastern Sicily. Infez Med 2005; 13: 79–85. 
* Presence of human herpesvirus-8 antibodies. 
Adapted from: Gazzard B, Clumeck N, d'Arminio Monforte A, Lundgren JD. Indicator disease-guided testing for HIV—the next 
step for Europe? HIV Med. 2008 Jul;9 Suppl 2:34-40. Review. 
